The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens

Toxicology in Vitro

Volumn 14, Issue 4, 2000, Pages 387-399

  Combes, R D ^a  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

Apoptosis; Carcinogens; Cell proliferation; Non genotoxic; Receptor binding; Structure activity relationships

Indexed keywords

CARCINOGEN;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CYTOTOXICITY; GENOTOXICITY; NONHUMAN; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CARCINOGENICITY TESTS; CARCINOGENS; CELL COMMUNICATION; CELL DIVISION; CELLS, CULTURED; GAP JUNCTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 0033931746     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(00)00026-6     Document Type: Review

References (74)

1. Adams J.M., Cory S. The Bcl-2 protein family. arbiters of cell survival Science. 281:1998;1322-1326.
2. Andreu J.M., Gorbunoff M.J., Medrano F.J., Rossi M., Timasheff S.N. Mechanism of colchicine binding to tubulin. Tolerance of substituents in ring C' of biphenyl analogues. Biochemistry. 30:1991;3777-3786.
3. Andreu J.M., Perez-Ramirez B., Gorunoff M.J., Ayala D., Timasheff S.N. Role of the colchicine A ring and its methoxy groups in the binding of tubulin and microtubule inhibition. Biochemistry. 37:1998;8356-8368.
4. Anon (1998) Non-genotoxic Carcinogens: Mechanisms Based Detection Methods, Ministere de L'Amenagement du Territoire et de L'Environnement, Paris.
5. Bai R., Pei X.F., Boye O., Getahun Z., Grover S., Bekisz J., Nguyen N.Y., Brossi A., Hamel E. Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine. Journal of Biological Chemistry. 271:1996;12639-12645.
6. Bannerjee A., Barnes L.D., Luduena R.F. The role of the B-ring of colchicine in the stability of the colchicine-tubulin complex. Biochimica et Biophysica Acta. 913:1987;138-144.
7. Beutler J.A., Hamel E., Vlietinck A.J., Haemers A., Rajan P., Roitman J.N., Cardellina J.H., Boyd M.R. Structure-activity requiremnets for flavone cytotoxicity and binding to tubulin. Journal of Medicinal Chemistry. 41:1998;2333-2338.
8. Butterworth B.E., Conolly R.B., Morgan K.T. A strategy for establishing the mode of action of chemical carcinogens as a guide for approaches to risk assessment. Cancer Letters. 93:1995;129-146.
9. Campenosi P., Ottagio L., Moro F., Urbini S., Bogliolo M., Zunino A., Camoriano A., Inga A., Gentile S.L., Pellegata N.S., Bonassi S., Bruzzone E., Iannone R., Piasni R., Menichini P., Ranzani G.N., Bonatti S., Abbondandolo A., Fronza G. Study on aneuploidy and p53 mutations in astrocytomas. Cancer Genetics and Cytogenetics. 88:1996;95-102.
10. Canuto R.A., Muzio G., Bonelli G., Maggiora M., Autelli R., Barbiero G., Costelli P., Brossa O., Baccino F.M. Peroxisome proliferators induce apoptosis in hepatoma cells. Cancer Detection and Prevention. 22:1998;357-366.
11. Chevalier S., Roberts R.A. G1-arrested FaO cells re-enter the cell cycle upon stimulation with the rodent non-genotoxic hepatocarcinogen nafenopin. Carcinogenesis. 20:1999;1209-1213.
12. Christensen J.G., Gonzales A.J., Cattley R.C., Goldsworthy T.L. Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens. Cell Growth and Differentiation. 9:1998;815-825.
13. Combes R. D. (1997) Detection of nongenotoxic carcinogens: major barriers to replacement of the rodent bioassay? Animal Alternatives, Welfare and Ethics, ed. L. F. M. van Zutphen and M. Balls, pp. 627-634. Elsevier, Amsterdam.
14. Combes R. D. (2000). Endocrine disruptors; a critical review of in vitro and in vivo testing strategies for assessing their toxic hazard to humans. ATLA 28, 81-118.
15. Combes R., Balls M., Curren R., Fischbach M., Fusenig N., Kirkland D., Lasne C., Landolph J., LeBoeuf R., Marquardt H., McCormick J., Muller L., Rivedal E., Sabbioni E., Tanaka N., Vasseur P. and Yamasaki H. (1999) Cell transformation assays as predictors of human carcinogenicity. The report and recommendations of ECVAM Workshop 39. ATLA 27, 745-767.
16. Combes R.D., Judson P. The use of artificial intelligence systems for predicting toxicity. Pesticide Science. 45:1995;179-194.
17. Corton J.C., Bocos C., Moreno E.S., Merritt A., Cattley R.C., Gustafsson J.A. Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes. Biochemie. 79:1997;151-162.
18. Cunningham A., Klopman G., Rosenkranz H.S. The carcinogenicity of diethylstilbestrol. structural evidence for a non-genotoxic mechanism Archives of Toxicology. 70:1996;356-361.
19. Cunningham A.R., Klopman G., Rosenkranz H.S. Identification of structural features and associated mechanisms of action for carcinogens in rats. Mutation Research. 405:1998;9-28.
20. Cunningham A.R., Rosenkranz H.S., Klopman G. Structural analysis of a group of phytoestrogens for the presence of a 2-D geometric descriptor associated with non-genotoxic carcinogens and some estrogens. Proceedings of the Society for Experimental Biology and Medicine. 217:1998;288-292.
21. Cunningham A.R., Rosenkranz H.S., Zhang Y.P., Klopman G. Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice. the carcinogenic potency database Mutation Research. 398:1998;1-17.
22. Daux W.L., Sweenson D.C., Strong P.D., Korach K.S., McLachlan J., Metzler M. Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity. Molecular Pharmacology. 26:1984;520-525.
23. Devereux T. R., Risinger J. I. and Barrett J. C. (1999) Mutations and altered expression of human cancer genes: What they tell us about causes. In: D.B. McGregor, J.M. Rice and S. Venitt (Eds), The Use of Short- and Medium-Term Test for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation. IARC Scientific Publications no. 146, pp. 19-42. International Agency for Research on Cancer, Lyon.
24. Dhalluin S., Elia Z., Poirot O., Gate L., Pages N., Tapiero H., Vasseur P., Nguyen-Ba G. Apoptosis inhibition and ornithine decarboxylase superinduction as early epigenetic events in morphological transformation of Syrian hamster embryo cells exposed to 2-methoxyacetaldehyde, a metabolite of 2-methoxyethanol. Toxicology Letters. 105:1999;163-175.
25. Dulvenvoorden W.C., Maier P. Non-genotoxic carcinogens shift cultured hepatocytes into G1 cell cycle phase. influence of tissue oxygen tension on cells with different ploidy European Journal of Cell Biology. 64:1994;368-375.
26. Eacho P.I., Foxworthy P.S., Herron D.K. Tetrazole substituted acetophenone peroxisome proliferators. structure-activity relationships and effects on hepatic lipid metabolism Gibson G.G., Lake B. Peroxisomes: Biology and Importance in Toxicology and Medicine. 1993;343-372 Taylor & Francis, London.
27. ECETOC (1997) ECETOC Monograph No. 27-Aneuploidy, European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, 172 pp.
28. Elcock F.J., Chipman J.K., Roberts R.A. The rodent nongenotoxic hepatocarcinogen and peroxisome proliferator nafenopin inhibits intercellular communication in rat but not guinea-pig hepatocytes, perturbing S-phase but not apoptosis. Archives of Toxicology. 72:1998;439-444.
29. Endo Y., Shimazu M., Fukusawa H., Driedger P.E., Kimura K., Tomioka N., Itai A., Shudo K. Synthesis, computer modeling and biological evaluation of novel protein kinase C agonsists based on a 7-membered lactam moiety. Bioorganic Medical Chemical Letters. 9:1999;173-178.
30. Endo Y., Takehana S., Ohno M., Driedger P.E., Stabel S., Mizutani M.Y., Tomioka N., Itai A., Shudo K. Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase C delta by synthesis of hydrophobically modified teleocidin-mimicking benzolactams and computational docking simulation. Journal of Medicinal Chemistry. 41:1998;1476-1496.
31. Feller D.R., Intrasuksri U. Structural requirements for peroxisome proliferation by phenoxyacetic and fatty acid analogues in primary cultures of rat hepatocytes. Gibson G.G., Lake B. Peroxisomes: Biology and Importance in Toxicology and Medicine. 1993;373-393 Taylor & Francis, London.
32. Gelman L., Fruchart J.C., Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cellular and Molecular Life Sciences. 55:1999;932-943.
33. Goldsworthy T.L., Conolly R.B., Fransson-Steen R. Apoptosis and cancer risk assessment. Mutation Research. 365:1996;71-90.
34. Hasmall S.C., Roberts R.A. The perturbation of apoptosis and mitosis by drugs and xenobiotics. Pharmacology and Therapeutics. 82:1999;63-70.
35. Hertz R., Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicology Letters. 102-103:1998;85-90.
36. Hildebrand H., Kempka G., Mahnke A. Determination of apoptosis in primary rat hepatocytes by real-time quantitative PCR (TaqMan PCR). Toxicology in Vitro. 13:1999;561-565.
37. Holder J.W., Elmore E., Barrett J.C. Gap junction function and cancer. Cancer Research. 53:1993;3475-3485.
38. Irie K., Hagiwara N., Tokuda H., Koshinizu K. Structure-activity studies of the indole alkaloid tumor promoter. Carcinogenesis. 8:1987;547-552.
39. Itai A., Kato Y., Tomioka N., Iitaka Y., Endo Y., Hasegawa M., Shudo K., Fujiki H., Sakai S. A receptor model for tumour promoters. rational superposition of teleocidins and phorbol esters Proceedings of the National Academy of Sciences of the U.S.A. 85:1988;3688-3692.
40. Krauter G., Von Der Lieth C.W., Schmidt R., Hecker E. Structure/activity relationships of polyfunctional diterpenes of the tigliane type. A pharmacophore model for protein-kinase-C activators based on structure/activity studies and molecular modelling of the tumor promoters 12-0-tetradecanoylphorbol 13-acetate and 3-0-tetradeconoylingenol. European Journal of Biochemistry. 242:1996;417-427.
41. Lake B.G., Lewis D.F.V. Stucture-activity relationships for chemically induced peroxisome proliferation in mammalian liver. Gibson G.G., Lake B. Peroxisomes: Biology and Importance in Toxicology and Medicine. 1993;313-342 Taylor & Francis, London.
42. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 386:1997;623-627.
43. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
44. Lewis D.F.V., Lake B.G. Molecular modelling of the rat peroxisome proliferator-activated receptor- (rPPAR) by homology with the human retinoic acid X receptor- (HRXR) and investigations of ligand binding interactions 1. QSARs Toxicology in Vitro. 12:1998;619-632.
45. src-mediated phosphorylation of connexin 43, a gap junction protein. Journal of Biological Chemistry. 270:1995;12751-12761.
46. Medrano F.J., Andreu J.M., Gorbunoff M.J., Timasheff S.N. Roles of colchicine rings B and C in the binding process to tubulin. Biochemistry. 28:1989;5589-5599.
47. Mounho B.J., Thrall B.D. The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicology and Applied Pharmacology. 159:1999;125-133.
48. Nishiwaki S., Fujiki H., Suganuma M., Furuya-Suguri H., Matsushima R., Iida Y., Ojika M., Yamada K., Uemura D., Yasumoto T., Schmitz F.J., Sugimura T. Structure-activity relationship within a series of okadaic acid derivatives. Carinogenesis. 11:1990;1837-1841.
49. Nguyen-Ba G., Vasseur P. Epigenetic events during the process of cell transformation induced by carcinogens. Oncology Reports. 6:1999;925-932.
50. Powell C.J., Berry C.L. Non-genotoxic or epigenetic carcinogenesis. Ballantyne B., Marrs T.C., Syversen T. General And Applied Toxicology, Second Edition. 1999;1119-1135 Macmillan Reference Ltd, London.
51. Prakash V., Timasheff S.N. Mechanism of interaction of vinca alkaloids with tubulin. Biochemistry. 30:1991;873-880.
52. Purchase I.F.H. Current knowledge of the mechanisms of carcinogenicity. genotoxins versus non-genotoxins Human and Experimental Toxicology. 13:1994;17-28.
53. Roberts R.A. Non-genotoxic hepatocarcinogenesis. suppression of apoptosis by peroxisome proliferators Annals of New York Academy of Sciences. 804:1996;588-611.
54. Rose B., Mehta P.P., Lowenstein W.R. Gap-junction protein gene suppresses tumorigenicity. Carcinogenesis. 14:1993;1073-1075.
55. Rosenkranz H.S., Liu M., Cunningham A., Klopman G. Application of structural concepts to evaluate the potential carcinogenicity of natural products. Environmental Research. 5:1996;79-98.
56. Rosenkranz M., Rosenkranz H.S., Klopman G. Intercellular communication, tumor promotion and non-genotoxic carcinogenesis. relationships based upon structural considerations Mutation Research. 38:1997;171-188.
57. Rosenkranz H.S., Zhang Y.P., Klopman G. Risk identification using structural concepts. the potential carcinogenicity of praziquantel Regulatory Toxicology and Pharmacology. 22:1995;152-161.
58. Schulte-Hermann R., Bursch W., Marian B. and Grasl-Kraupp B. (1999) Active cell death (apoptosis) and cellular proliferation as indicators of exposure to carcinogens. IARC Scientific Publications no. 146, pp. 273-285. International Agency for Research on Cancer, Lyon.
59. Staretz M.E., Hastie S.B. Synthesis and tubulin binding of novel C-10 analogues of colchicine. Journal of Medicinal Chemistry. 36:1993;758-764.
60. ter Haar E., Rosenkranz H.S., Hamel E., Day B.W. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorganic and Medicinal Chemistry. 10:1996;1659-1671.
61. Trosko J.E., Ruch R.J. Cell-cell communication in carcinogenesis. Frontiers of Bioscience. 15:1998;D208-236.
62. Upham B.L., Deocampo N.D., Wurl B., Trosko J.E. Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. International Journal of Cancer. 78:1998;491-495.
63. van den Heuvel J.P. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicological Sciences. 47:1999;1-8.
64. Velculescu V.E., El-Deiry W.S. Biological and clinical importance of the p53 tumor suppressor gene. Clinical Chemistry. 42:1996;858-868.
65. Wallin M., Hartley-Asp B. Effects of potential aneuploidy inducing agents on microtubule assembly in vitro. Mutation Research. 287:1993;17-22.
66. Wattenberg E.V., Uemura D., Byron K.L., Villereal M.L., Fujiki H., Rosner M.R. Structure-activity studies of the nonphorbol tumor promoter palytoxin in swiss 3T3 cells. Cancer Research. 49:1989;5837-5842.
67. Waxman D.J. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. Journal of Endocrinology. 150:1996;S129-147.
68. Weinberg R.A. How cancer arises. Scientific American. 275:1996;32-40.
69. White R., Jobling S., Hoare S.A., Sumpter J.P., Parker M.G. Environmentally persistent alkylphenolic compounds are estrogenic. Endocrinology. 135:1994;175-182.
70. Wiese T.E., Polin L.A., Palomino E., Brooks S.C. Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta. a 3D QSAR study Journal of Medicinal Chemistry. 40:1997;3659-3669.
71. Welshons W.V., Nagel S.C., Thayer K.A., Judy B.M., Vom Saal F.S. Low-dose bioactivity of xenoestrogens in animals. fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice Toxicology and Industrial Health. 15:1999;12-25.
72. Yamasaki H. Cellular and molecular methods to study the role of gap junctional intercellular communication in toxicology. Toxicology in Vitro. 11:1997;535-542.
73. Yamasaki H., Ashby J., Bignami M., Jongen W., Linnainmaa K., Newbold R.F., Bguyen-Ba G., Parodi S., Rivedal E., Schiffmann D., Simons J.W.I.M., Vasseur P. Nongenotoxic carcinogens. development of detection methods based on mechanisms Mutation Research. 353:1996;47-63.
74. Zhou X.J., Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. S4:1992;1-16.